Isolation and identification of a major impurity in a new bulk drug candidate by preparative LC, ESI-MSn, LC-MS-MS, and NMR

Journal of Chromatographic Science

Volumn 45, Issue 1, 2007, Pages 45-49

  Li, Ning ^a   Yang, Jing ^a   Qin, Fang ^a   Li, Famei ^a   Gong, Ping ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33846214776     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/45.1.45     Document Type: Article

References (15)

1. International Conference on the Harmonization of the Technical Requirement for Registration of Pharmaceuticals for Human Use (ICH). Q3A(R): Impurities in New Drug Substances, Revised guideline. ICH, Geneva, Switzerland, 2002.
2. S. Gorog. Chemical and analytical characterization of related organic impurity in drugs. Anal. Bioanal. Chem. 377: 852-62 (2003).
3. K. Laniewski, M. Vagero, E. Forsberg, T. Forngren, and G. Hagman. Complementary use of gas chromatography-mass spectrometry, gas chromatography-atomic emission detection and nuclear magnetic resonance for identification of pharmaceutically related impurities of unknown structures. J. Chromatogr. A. 1027: 93-102 (2004).
4. J. Ermer and M. Vogel. Application of hyphenated LC-MS techniques in pharmaceutical analysis. Biomed. Chromatogr. 14: 373-83 (2000).
5. Y. Wu. The use of liquid chromatography-mass spectrometry for the identification of drug degradation products in pharmaceutical formulations. Biomed. Chromatogr. 14: 384-96 (2000).
6. Y.R. Kumar, J.M. Babu, M.S.P. Sarma, B. Seshidhar, S.S. Reddy, G.S. Reddy, and K. Vyas. Application of LC-MS/MS for the identification of a polar impurity in mosapride, a gastroprokinetic drug. J. Pharm. Biomed. Anal. 32: 361-68 (2003).
7. J.K. Roberts and R.J. Smith. Use of liquid chromatography-nuclear magnetic resonance spectroscopy for the identification of impurities in drug substances. J. Chromatogr. A 677: 385-89 (1994).
8. S.X. Peng. Hyphenated HPLC-NMR and its application in drug discovery. Biomed. Chromatogr. 14: 430-41 (2000).
9. J.C. Lindon, J.K. Nicholson, and I.D. Wilson. Directly coupled HPLC-NMR-MS in pharmaceutical research and development. J. Chromatgr. B Biomed. Sci. Appl. 748: 233-58 (2000).
10. L. Miller and R. Bergeron. Preparative liquid chromatographic isolation of unknown impurities in Arbidol and SI-5. J. Chromatogr. A 658: 489-96 (1994).
11. G.J. Lehr, T.L. Barry, G.M. Hanna, and S.W. Zito. Isolation and identification of process impurities in trimethoprim drug substance by high-performance liquid chromatography, atmospheric pressure chemical ionization liquid chromatography/mass spectrometry and nuclear magnetic resonance spectrometry. J. Pharm. Biomed. Anal. 19: 373-89 (1999).
12. G.J. Lehr and T.L. Barry. LC determination of impurities in methoxsalen drug substance: isolation and identification of isopimpinellin as a major impurity by atmospheric pressure chemical ionization LC/MS and NMR. J. Pharm. Biomed. Anal. 33: 627-37 (2003).
13. K.V. Krishna Reddy and J.M. Babu. Identification and characterization of potential impurities of donepezil. J. Pharm. Biomed. Anal. 35: 1047-58 (2004).
14. Y.R. Kumar, V.V.N.K.V. Prasad Raju, R.R. Kumar, S. Eswaraiah, K. Mukkanti, M.V. Suryanarayana, M.S. Reddy, and K. Vyas. Structral identification and characterization of impurities in moxifloxacin. J. Pharm. Biomed. Anal. 34: 1125-29 (2004).
15. K.M. Alsante, P. Boutros, M.A. Couturier, R.C. Friedmann, J.W. Harwood, G.J. Horan, A.J. Jensen, Q. Liu, L.L. Lohr, R. Morris, J.M. Raggon, G.L. Reid, D.P. Santafianos, T.R. Sharp, J.L. Tucker, and G.E. Wilcox. Pharmaceutical impurity identification: a case study using a multidisciplinary approach. J. Pharm. Sci. 93: 2296-2309 (2004).